Teva Pharmaceutical Industries Ltd. is looking to close a deal with a biosimilar partner soon, according to Global Generic Medicines CEO Sigurdur Olafsson. The head of the generics business said biosimilars will be a “key ingredient” to the future of Teva, but acknowledged the recipe for success will require the help of a partner – and quickly.
Closing a deal in the biosimilar space is an important business priority for Teva in the near-term; the company’s generic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?